Effects of vitamin D supplementation on glycated haemoglobin and fasting glucose levels in hypertensive patients: a randomized controlled trial.

What Was Tested

This randomized controlled trial looks at Vitamin D, K2, Magnesium and Zinc.

Who Took Part

The study group was 200 people.

PubMed indexes the participants as middle-aged adults and older adults, both men and women.

The researchers enrolled 200 people with arterial hypertension and 25-hydroxyvitamin D [25(OH)D] concentrations <30 ng/mL.

How the Study Was Run

The design is described as randomized, double-blind and placebo-controlled.

Random assignment meant chance, not the researchers, decided who got Vitamin D, K2, Magnesium and Zinc and who got the comparison, which limits bias.

Blinding on both sides kept the people and researchers unaware of who received Vitamin D, K2, Magnesium and Zinc.

The comparison arm used a placebo, so changes seen with Vitamin D, K2, Magnesium and Zinc could be set against what happens without it.

The Styrian Vitamin D Hypertension Trial was a single-centre, double-blind, placebo-controlled study conducted between 2011 and 2014 at the Medical University of Graz, Austria.

The present study was a post hoc analysis that incorporated an analysis of covariance (ancova) approach, while adjusting for baseline differences.

What Was Measured

The subject headings attached to it are Blood Glucose, Dietary Supplements, Fasting, Glycated Hemoglobin, Hypertension, Obesity and Vitamin D.

Author keywords: cardiovascular disease, randomised trial and type 2 diabetes.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Vitamin D, K2, Magnesium and Zinc in 200 people.

Results are reported in around 4 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2016 (Diabetes, obesity & metabolism), a journal based in England.

More context: the Vitamin D, K2, Magnesium and Zinc compound page, all human trials.